BAIT
BRD4
CAP, HUNK1, HUNKI, MCAP
bromodomain containing 4
GO Process (10)
GO Function (4)
GO Component (5)
Gene Ontology Biological Process
- cellular response to DNA damage stimulus [IMP]
- chromatin remodeling [IDA]
- negative regulation of DNA damage checkpoint [IMP]
- positive regulation of G2/M transition of mitotic cell cycle [IMP]
- positive regulation of I-kappaB kinase/NF-kappaB signaling [IDA]
- positive regulation of transcription elongation from RNA polymerase II promoter [IDA, IMP]
- positive regulation of transcription from RNA polymerase II promoter [IDA]
- regulation of inflammatory response [IDA]
- regulation of phosphorylation of RNA polymerase II C-terminal domain [IDA]
- regulation of transcription involved in G1/S transition of mitotic cell cycle [IMP]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Homo sapiens
PREY
CTNNB1
CTNNB, MRD19, armadillo, OK/SW-cl.35
catenin (cadherin-associated protein), beta 1, 88kDa
GO Process (48)
GO Function (20)
GO Component (23)
Gene Ontology Biological Process
- Wnt signaling pathway [IDA]
- adherens junction assembly [IMP]
- androgen receptor signaling pathway [NAS]
- apoptotic process [TAS]
- canonical Wnt signaling pathway [IDA]
- canonical Wnt signaling pathway involved in negative regulation of apoptotic process [IMP]
- canonical Wnt signaling pathway involved in positive regulation of cardiac outflow tract cell proliferation [ISS]
- canonical Wnt signaling pathway involved in positive regulation of epithelial to mesenchymal transition [IMP]
- cell adhesion [IMP]
- cellular component disassembly involved in execution phase of apoptosis [TAS]
- cellular response to growth factor stimulus [IMP]
- cellular response to indole-3-methanol [IDA]
- embryonic skeletal limb joint morphogenesis [ISS]
- endothelial tube morphogenesis [IMP]
- epithelial to mesenchymal transition [TAS]
- hair cell differentiation [TAS]
- innate immune response [TAS]
- muscle cell differentiation [TAS]
- negative regulation of cell proliferation [IDA]
- negative regulation of mitotic cell cycle, embryonic [ISS]
- negative regulation of protein sumoylation [IDA]
- negative regulation of transcription, DNA-templated [IMP]
- patterning of blood vessels [IC]
- positive regulation of DNA-templated transcription, initiation [IC]
- positive regulation of apoptotic process [IDA]
- positive regulation of epithelial to mesenchymal transition [IGI]
- positive regulation of heparan sulfate proteoglycan biosynthetic process [IMP]
- positive regulation of histone H3-K4 methylation [IC]
- positive regulation of muscle cell differentiation [TAS]
- positive regulation of neuroblast proliferation [ISS]
- positive regulation of transcription from RNA polymerase II promoter [IDA, IMP]
- positive regulation of transcription, DNA-templated [IDA, IMP]
- positive regulation of type I interferon production [TAS]
- protein localization to cell surface [IMP]
- regulation of angiogenesis [TAS]
- regulation of calcium ion import [IDA]
- regulation of cell fate specification [IBA]
- regulation of centriole-centriole cohesion [IDA]
- regulation of centromeric sister chromatid cohesion [IMP]
- regulation of fibroblast proliferation [TAS]
- regulation of nephron tubule epithelial cell differentiation [ISS]
- regulation of protein localization to cell surface [IDA]
- regulation of smooth muscle cell proliferation [IMP]
- response to drug [IEP]
- response to estradiol [IDA]
- single organismal cell-cell adhesion [IMP]
- stem cell maintenance [TAS]
- sympathetic ganglion development [ISS]
Gene Ontology Molecular Function- I-SMAD binding [IPI]
- R-SMAD binding [IPI]
- RNA polymerase II activating transcription factor binding [IPI]
- SMAD binding [IPI]
- alpha-catenin binding [IPI]
- androgen receptor binding [NAS]
- cadherin binding [IPI]
- enzyme binding [IPI]
- estrogen receptor binding [IPI]
- euchromatin binding [IDA]
- ion channel binding [IPI]
- kinase binding [IPI]
- nuclear hormone receptor binding [IPI, TAS]
- protein C-terminus binding [IPI]
- protein binding [IPI]
- protein phosphatase binding [IPI]
- signal transducer activity [NAS]
- transcription coactivator activity [IDA, IMP]
- transcription factor binding [IPI, TAS]
- transcription regulatory region DNA binding [IDA]
- I-SMAD binding [IPI]
- R-SMAD binding [IPI]
- RNA polymerase II activating transcription factor binding [IPI]
- SMAD binding [IPI]
- alpha-catenin binding [IPI]
- androgen receptor binding [NAS]
- cadherin binding [IPI]
- enzyme binding [IPI]
- estrogen receptor binding [IPI]
- euchromatin binding [IDA]
- ion channel binding [IPI]
- kinase binding [IPI]
- nuclear hormone receptor binding [IPI, TAS]
- protein C-terminus binding [IPI]
- protein binding [IPI]
- protein phosphatase binding [IPI]
- signal transducer activity [NAS]
- transcription coactivator activity [IDA, IMP]
- transcription factor binding [IPI, TAS]
- transcription regulatory region DNA binding [IDA]
Gene Ontology Cellular Component
- adherens junction [IDA]
- beta-catenin destruction complex [IDA]
- beta-catenin-TCF7L2 complex [IDA]
- catenin complex [IDA]
- cell cortex [IDA]
- cell junction [IDA, TAS]
- cell periphery [IDA]
- cell-cell adherens junction [IDA]
- cell-cell junction [IDA]
- centrosome [IDA]
- cytoplasm [IDA]
- cytosol [IDA, TAS]
- extracellular vesicular exosome [IDA]
- focal adhesion [IDA]
- lateral plasma membrane [IDA]
- membrane [ISS]
- nuclear euchromatin [IDA]
- nucleoplasm [TAS]
- nucleus [IDA]
- perinuclear region of cytoplasm [IDA]
- plasma membrane [IDA]
- protein-DNA complex [IDA]
- transcription factor complex [IDA]
Homo sapiens
Affinity Capture-MS
An interaction is inferred when a bait protein is affinity captured from cell extracts by either polyclonal antibody or epitope tag and the associated interaction partner is identified by mass spectrometric methods.
Publication
Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer.
BET bromodomain inhibitors (BBDIs) are candidate therapeutic agents for triple-negative breast cancer (TNBC) and other cancer types, but inherent and acquired resistance to BBDIs limits their potential clinical use. Using CRISPR and small-molecule inhibitor screens combined with comprehensive molecular profiling of BBDI response and resistance, we identified synthetic lethal interactions with BBDIs and genes that, when deleted, confer resistance. We ... [more]
Mol Cell Dec. 18, 2019; 78(6);1096-1113.e8 [Pubmed: 32416067]
Throughput
- High Throughput
Curated By
- BioGRID